Soligenix, Inc. (SNGX)
NASDAQ·Healthcare·Biotechnology
$0.43
-69.83%
Mkt Cap $12.10M
EPS — Estimate vs Actual
Revenue — Estimate vs Actual
Quarterly History
| Q2 2026 Apr 3, 2026 | — | — | — | -$0.27 | $0.32 | +218.52% | — | — |
| Q4 2025 Nov 7, 2025 | — | — | — | -$0.63 | -$0.58 | +7.94% | — | — |
| Q3 2025 Aug 14, 2025 | — | — | — | -$0.79 | -$0.82 | -3.80% | — | — |
| Q2 2025 May 9, 2025 | — | — | — | -$0.67 | -$1.06 | -58.21% | — | — |
| Q1 2025 Mar 21, 2025 | $200.00K | $6.35K | -96.82% | -$0.95 | -$1.14 | -20.00% | — | — |
| Q4 2024 Nov 8, 2024 | $200.00K | — | — | -$1.09 | -$0.78 | +28.44% | — | — |
| Q3 2024 Aug 9, 2024 | $200.00K | $2.34K | -98.83% | -$2.11 | -$1.31 | +37.91% | — | — |
| Q2 2024 May 10, 2024 | $200.00K | $117.03K | -41.49% | -$3.20 | -$2.88 | +10.00% | — | — |
| Q1 2024 Mar 15, 2024 | $200.00K | $244.81K | +22.41% | -$3.04 | -$2.56 | +15.79% | — | — |
| Q4 2023 Nov 13, 2023 | $200.00K | $130.44K | -34.78% | -$7.04 | -$2.56 | +63.64% | — | — |
| Q3 2023 Aug 21, 2023 | $200.00K | $206.93K | +3.46% | -$7.84 | -$2.72 | +65.31% | — | — |
| Q2 2023 May 15, 2023 | $200.00K | $257.18K | +28.59% | -$20.00 | -$5.76 | +71.20% | — | — |
| Q1 2023 Mar 31, 2023 | $200.00K | $366.07K | +83.03% | -$1.12 | -$4.58 | -308.93% | — | — |
| Q4 2022 Nov 10, 2022 | $200.00K | $166.14K | -16.93% | -$19.19 | -$19.19 | +0.00% | — | — |
| Q3 2022 Aug 12, 2022 | $200.00K | $228.64K | +14.32% | -$16.79 | -$14.39 | +14.29% | — | — |
| Q2 2022 May 13, 2022 | $100.00K | $188.06K | +88.06% | -$14.39 | -$23.99 | -66.71% | — | — |
| Q1 2022 Mar 29, 2022 | $200.00K | $275.65K | +37.83% | -$19.19 | -$26.39 | -37.52% | — | — |
| Q4 2021 Nov 12, 2021 | $420.00K | $186.20K | -55.67% | -$31.18 | -$21.59 | +30.76% | — | — |
| Q3 2021 Aug 13, 2021 | $540.00K | $214.82K | -60.22% | -$26.39 | -$11.99 | +54.57% | — | — |
| Q2 2021 May 17, 2021 | $560.00K | $147.59K | -73.64% | -$26.39 | -$14.39 | +45.47% | — | — |